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Background: Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine
(SP) decreases placental parasitaemia, thus improving birth outcomes. Zambian policy recommends monthly
SP-IPTp doses given presumptively during pregnancy at each antenatal examination, spaced one month apart after
16 weeks of gestation. The effectiveness of SP-IPTp was evaluated in Zambia where a recent study showed moderate
prevalence of Plasmodium falciparum parasites with genetic mutations that confer SP resistance.
Methods: HIV-negative women were enrolled at the time of delivery at two facilities in Mansa, Zambia, an area of high
malaria transmission. Women were interviewed and SP exposure was determined by antenatal card documentation or
self-reports. Using Poisson regression modelling, the effectiveness of SP-IPTp was evaluated for outcomes of parasitaemia
(microscopic examination of maternal peripheral, cord, and placental blood films), maternal anaemia (Hb < 11 g/dl),
placental infection (histopathology), and infant outcomes (low birth weight (LBW), preterm delivery, and small for
gestational age) in women who took 0–4 doses of SP-IPTp.
Results: Participants included 435 women, with a median age of 23 years (range 16–44). Thirty-four women took zero
doses of SP-IPTp, while 115, 142 and 144 women took one, two, or ≥ three doses, respectively. Multivariate Poisson
regression models considering age, mosquito net usage, indoor residual spraying, urban home, gravidity, facility, wet
season delivery, and marital status showed that among paucigravid women ≥ two doses of SP-ITPp compared to one or
less doses was associated with a protective effect on LBW (prevalence ratio (PR) 0.33, 95% confidence interval (CI)
0.12–0.91) and any infection (PR 0.76, CI 0.58–0.99). Multivariate models considering SP-IPTp as a continuous variable
showed a protective dose–response association with LBW (paucigravid women: PR 0.54, CI 0.33–0.90, multigravid
women: PR 0.63, CI 0.41–0.97).
Conclusions: In Mansa, Zambia, an area of moderate SP resistance, ≥ two doses of SP-IPTp were associated with
a protective effect from malaria in pregnancy, especially among paucigravid women. Each dose of SP-IPTp
contributed to a 46 and 37% decrease in the frequency of LBW among paucigravid and multigravid women,
respectively. SP-IPTp remains a viable strategy in this context.
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Malaria during pregnancy is dangerous for women and
infants. Approximately 32 million pregnancies per year
occurring in regions of sub-Saharan Africa are at risk for
malaria [1], and an estimated 200,000 of them occur in
Zambia [2]. Malaria infection during pregnancy can result
in adverse effects for both mother and infant, including
severe maternal anaemia, low birth weight (LBW), and in-
creased perinatal and infant mortality; adverse effects are
more likely during a woman’s first or second pregnancy
[3]. Women infected with HIV have a higher risk for
adverse pregnancy outcomes [4], and the beneficial effects
of SP-IPTp can be compromised by HIV status. Malaria is
a substantial health concern in Zambia. In 2010, at the
time of the study, the national prevalence of malaria
parasitaemia in children under five years old was 16%;
Luapula Province had the highest prevalence with 51%
of children under five years infected [5]. The Zambian
Ministry of Health recommends preventive measures to
protect pregnant women from malaria including sleeping
under an insecticide-treated mosquito net (ITN), and
taking sulphadoxine-pyrimethamine (SP) regardless of
malaria parasitaemia, after 16 weeks of gestation as inter-
mittent preventive treatment in pregnancy (IPTp) with SP
(SP-IPTp) [6]. At the time of the study, the Zambia guide-
lines recommended three doses of SP-IPTp, spaced one
month apart in the second and third trimesters of preg-
nancy. Subsequently, Zambian guidelines were updated to
be in line with the WHO 2012 recommendations for
monthly dosing of SP-IPTp given at each antenatal visit in
the second and third trimesters [7].
SP-IPTp protects from malaria during pregnancy, likely
by clearing existing asymptomatic infections and by pre-
venting new infections from occurring during the period
after treatment, due to SP’s long half-life [8]. Earlier
studies showed that SP-IPTp decreased placental malaria
parasitaemia [9-17], maternal anaemia [11,12,15,18], and
LBW [15-17,19]. Parasite resistance to SP threatens the ef-
fectiveness of SP-IPTp. Indeed malaria parasites developed
SP resistance in Zambia [20] and in 2006 the adequate
clinical and parasitological response for SP in children in
Zambia was only 77% [21]. Other studies in sub-Saharan
Africa suggest that SP-IPTp effectiveness is weakening
[22,23]. The presence of Plasmodium falciparum dihy-
dropteroate synthase (dhps) and dihydrofolate reductase
(dhfr) mutations are associated with SP drug resistance in
the Plasmodium parasite. The quintuple mutant haplo-
type, consisting of the N51I, C59R, S108N substitutions
in dhfr and the A437G and K540E substitutions in
dhps, has been associated with SP treatment failure
[24]. A study conducted concurrently to the present
study in Mansa, Zambia showed that among 84 speci-
mens with complete haplotypes at dhfr loci 51, 59 and
108, and dhps loci 437 and 540, 61% had the quintuplemutant [25]. In comparison to other malaria regions,
Zambia has intermediate frequencies of mutations that
cause resistance to SP. A study conducted in Zambia
showed that HIV-infected women require monthly dosing
to obtain the benefits of SP-IPTp [26], however there is
no comparable study for HIV-negative women in Zambia.
This study was designed in collaboration with the Malaria
in Pregnancy (MiP) Consortium as part of a multi-site in-
vestigation into the effectiveness of SP-IPTp, where Zambia
is one of eight sites in six countries, including Mali (two
sites), Burkina Faso, Uganda, Kenya, and Malawi (two sites).
Three modules were designed, including a therapeutic effi-
cacy evaluation, determination of molecular markers of SP
resistance and a retrospective cohort assessment of birth
outcomes. This manuscript describes the Zambia birth
outcomes component; the compiled analysis from the
multi-site analysis and results from the other modules and
sites are reported separately [25,27-30].
Methods
Study design and population
In Zambia, the retrospective-cohort birth outcomes study
was conducted in Mansa, Luapula Province, at the Mansa
General Hospital and Senama Rural Health Clinic. Both
facilities serve the Mansa District population; Mansa
General Hospital is a level-2 referral hospital with 326
beds and is located 0.5 km from the Mansa District Health
Management Office (DHMO), and Senama Rural Health
Clinic is situated 3 km from the DHMO, outside Mansa
urban centre and has 20 beds [31]. The study period was
from December 2009 to December 2010, spanning
portions of the 2009–2010 and 2010–2011 rainy seasons,
occurring generally from November to April. Women
who presented for delivery at the participating facilities
were enrolled by midwives trained in sample collection
procedures related to this study. Inclusion criteria were:
having an available SP-IPTp and HIV-test history
recorded on an antenatal card, a singleton delivery,
being ≥ 16 years old, and providing informed consent.
Since HIV-positive women are recommended to take co-
trimoxazole prophylaxis to prevent opportunistic infec-
tions, and SP-IPTp is not advised for pregnant women on
co-trimoxazole due to toxicity concerns from simultan-
eous administration of the two drugs with similar mecha-
nisms of action [8], only HIV-negative women were
enrolled in this study. Women were excluded if they had
ever had a positive HIV test result, if after the 16th gesta-
tional week they received either a blood transfusion or an
anti-malarial medication other than SP-IPTp, if they deliv-
ered outside of the hospital, or if they lived outside the
Mansa District. Despite the requirement to enrol only
women who had an antenatal card, because stock-outs of
SP occurred during the study period, it was possible to
enrol women who did not take any SP-IPTp doses.
Mace et al. Malaria Journal  (2015) 14:69 Page 3 of 11Sometimes eligible women who birthed at the two
facilities could not be screened and enrolled because a
study-trained midwife was not on duty, or could not
accommodate specimen and data collection procedures in
addition to routine hospital responsibilities, or when study
materials were stocked out. To minimize the likelihood of
systematic selection bias, the study-trained midwives
included those of both supervisor and non-supervisor
status, and also included those that worked variable shifts,
including during the day and night time.
Parameters evaluated and outcome definitions
Enrolled women were interviewed using MiP Consortium-
designed data collection instruments for the multi-site
study, modified specifically for the Zambian context. Infor-
mation collected included: demographics, ITN ownership
and use, indoor residual spraying (IRS), and medical
history. Antenatal cards served as the primary source of
documented SP-IPTp dates. However, a small number of
self-reported SP-doses, which were commonly associated
with SP stock-outs at the antenatal clinics, were accepted.
When possible, these doses were verified with receipts
from purchase at pharmacies or from other medical re-
cords because women often filled the SP-IPTp prescription
and retained the receipt with her ANC card. During data
analysis, the dates of the non-antenatal clinic SP doses
were validated to ensure they were not duplicated with
those reported on the antenatal card. For all enrolled
women, the study team of nurse midwives attempted to
collect the following soon after delivery: haemoglobin (Hb)
measurements, blood smears from maternal peripheral,
placental and cord blood, placental specimens for histo-
pathology, infant birth weight, gestational age at delivery
assessed by Ballard score [32], and last menstrual period
(LMP). Babies with a birth weight of ≤2,500 g were
followed up at six weeks to assess mortality.
Moderate maternal anaemia was defined as Hb <11 g/dl;
severe maternal anaemia was Hb <8 g/dl. Placental infec-
tion according to histopathology was classified according
to the following guidelines: class 1: parasites present with
no pigment in monocytes or fibrin; class 2: parasites
present with pigment in monocytes +/− fibrin; class 3: par-
asites present with pigment in fibrin; class 4: no parasites,
pigment only indicating past infection; class 5: no parasites
or pigment present, indicating no infection [33]. Maternal,
cord and placental blood smears were examined for
presence of malaria parasites, plus parasite species and
density for those positive. Infants weighing ≤2,500 g at
birth were considered to be LBW; small for gestational
age (SGA) was defined as being less than the tenth
percentile in weight per gestational age determined by
a longitudinal ultrasound-derived foetal nomogram for
a sub-Saharan African population [34]. Preterm was de-
fined as birth at <37 weeks of completed gestation.Finally, a ‘composite poor birth outcome’ was defined
as any infant born with LBW, SGA or preterm.
Laboratory methods
Malaria blood smears
Thick and thin smears were prepared from finger-stick
blood samples following a standard protocol using a 5%
Giemsa solution [35]. Trained, on-site technicians read
thick blood smears to detect Plasmodium parasites and
to calculate the parasite density according to the number
of asexual parasites per 300 white blood cells (WBCs),
assuming a total of 8,000 WBCs per μl. A thick blood
smear was classified as negative if no asexual parasites
were identified after 1,000 WBCs were counted. Thin
blood smears were examined to determine Plasmodium
species. For quality control, all slides were sent to a
national-level laboratory and read a second time by a senior
microscopist. If the results of the two readings were dis-
crepant then the slide was read for a third time by a
national-level, senior microscopist for a final determination.
Upon delivery, samples of placenta and placental blood
were collected. An incision was made on the maternal side
of the placenta and pooled blood was collected for thick
smear examination as described for malaria blood smears.
Placental histopathology
Tissue samples from the maternal side of the placenta
were collected; dimensions were approximately 2 cm ×
2 cm in length and width, and 1 cm in depth. Specimens
were immediately placed in buffered formalin-filled bottles
and stored at room temperature. Within one month of
collection, specimens were sent to Tropical Disease
Research Centre (TDRC), Ndola, Zambia where tissues
were wax embedded within two weeks, sectioned, stained
with Gurr’s modified Giemsa or haematoxylin and eosin,
and examined independently by two senior pathologists
experienced in reading placental histopathology for
malaria. For discrepant results, specimens were reviewed
and consensus was determined. Placental histology was
classified on a five-point scale as described by Rogerson
et al. [33] and also characterized as active placental infec-
tion (class 1), chronic placental infections (classes 2 and 3),
and past malaria placental infection (class 4).
Sample size
Sample size was calculated for the main birth outcome of
interest, evidence of placental malaria by histopathology.
The major strata of interest for the primary independent
variable, SP-IPTp doses, was ‘two or more doses of SP’
(reflecting full uptake of the WHO IPTp recommenda-
tions) versus ‘one or less doses of SP’; based on the 2008
Zambian National Malaria Indicator Survey, 66% of
women surveyed received at least two doses of SP-IPTp
[36]. It was also estimated that 20% of untreated women
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least two doses of SP-IPTp would result in 5% of treated
women having placental malaria. To detect a decrease in
placental malaria from 20 to 5% with 66% of women in
the ‘two or more doses’ strata compared to one or less
doses of SP-IPTp and with a 95% confidence level (CI)
and a power of 0.8, 116 treated women and 60 untreated
women were needed for a total of 176 women. To account
for the design effect (DE = 2) of cluster sampling at the
health facility level, this sample was doubled to 352.
Accounting for possible losses due to problems with
specimen quality, 10% was added to this amount for a
total of 387 patients.Statistical analysis
Frequency counts and percentages were calculated for
subject characteristics. The primary outcome was placen-
tal infection according to histopathology; secondary out-
comes were LBW, preterm delivery, SGA, composite poor
birth outcome, maternal anaemia, and any infection
(defined as pathology class 1–4, OR blood smear positive
(maternal, placental or cord blood)). The independent
variable of interest was doses of SP-IPTp, evaluated for
three categorical SP-IPTp variables: (i) < two versus ≥ two
SP-IPTp doses, with the ≥ two SP-IPTp doses representing
full uptake of the WHO IPTp recommendations for sub-
Saharan African countries at the time of the study; (ii) <
three versus ≥ three SP-IPTp doses, with ≥ three SP-IPTpFigure 1 Flow chart of registered births and participant enrolment.doses reflecting full uptake of the Zambian national policy
at the time; and, (iii) two versus ≥ three SP-IPTp doses to
assess the added benefit between two doses and three or
more doses. All analyses were performed in SAS version
9.3 (SAS Institute, Inc, Cary, NC, USA) and PROC
GENMOD was used for all Poisson regression models
with robust standard errors [37]. Bivariate, unadjusted
prevalence ratios for the SP-IPTp effects were calculated
and multivariate Poisson regression models were fit to ad-
just for cofactors. Cofactors considered for the models
were: age group (<18, 18–35, >35), gravidity, sleeping
under an ITN the last night at home, living in a home
treated with IRS, living in an urban area, facility of enrol-
ment, delivering during the wet season (November–April),
marital status, and taking SP-IPTp doses outside of ante-
natal clinic visits. Cofactors included in the final adjusted
models were selected based on strength of association in
bivariate models (at the 0.1 level of significance for any
outcome), biological plausibility, model fit statistics, and
the number of outcome events. To assess if SP-IPTp
exhibited a dose–response trend, SP-IPTp was defined as
a continuous variable in unadjusted and multivariate
models. Finally, Pearson’s Chi-square tests were employed
to assess the effect of dose timing on outcomes. A two-
sided p-value <0.05 was considered statistically significant.
Human subjects review
Ethical approval for this study was obtained from insti-
tutional review boards at both the US Centers for
Table 1 Subject characteristics
Characteristic n/Na (%)
Aged <18 years old 42/432 (10)
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Diseases Research Centre in Zambia. All participating
women provided written informed consent.Aged ≥35 years old 33/432 (8)
Doses of SPb-IPTpc taken
0 doses 34/435 (8)
1 dose 115/435 (26)
2 doses 142/435 (33)
3 doses 135/435 (31)
4 doses 9/435 (2)
Primigravid women 159/433 (37)
Paucigravid women 218/432 (51)
Multigravid women 214/432 (50)
From rural communities 255/433 (59)
Married 365/433 (84)
Home is treated with indoor residual spraying 149/411 (35)
Owns an insecticide treated net (ITN) 217/435 (50)
Slept under ITN during the last night at home 180/435 (42)
Delivered during the wet season 345/434 (80)
Self-reported doses of SP-IPTp 33/435 (8)
aTotal contributing responses.
bSP = sulphadoxine pyrimethamine.
cIPTp = intermittent preventive treatment for malaria in pregnancy.
Table 2 Outcome frequencies
Outcome n/Na (%)
Placental infection by histopathology
Abnormal (classes 1–4) 162/435 (37)
Active infection (class 1) 18/435 (4)
Chronic infection (classes 2 and 3) 32/435 (7)
Past infection (class 4) 112/435 (26)
Low birth weight (LBW) infant 34/435 (8)
Preterm infant 61/429 (14)
Small for gestational age (SGA) infant 76/428 (18)




Infant death within six weeks of birth 6/431 (1)
Maternal anaemia
Moderate anaemia (≥8.0 Hb <11.0 g/dl) 157/435 (36)
Severe anaemia (Hb <8.0 g/dl) 14/435 (3)
Blood smear positive for malaria parasites
Maternal peripheral 21/419 (5)
Cord blood 9/428 (2)
Placental 19/430 (4)
Any smear 28/420 (7)
Parasite density (parasites/ul); min, max, median 106.7, >200,000, 3333.3
aNumber with outcome/total contributing responses.Results
During the study period, a total of 918 births were regis-
tered at the two health facilities (Figure 1). Of these, 128
(14%) births were screened and found ineligible. Reasons
for ineligibility included HIV positivity, non-singleton
birth, having taken an anti-malarial for acute malaria
infection, no antenatal card available (e.i., undocumented
HIV status), being from outside the Mansa District, and
for not delivering in one of the two hospitals. In addition
355 (39%) women were not enrolled because they refused
consent, or there was no trained midwife on duty with
sufficient time or study materials, or for other reasons.
The most common reason that a birth was not screened
for enrolment was because a trained midwife was not on
duty, or was unable to conduct study procedures and still
manage work priorities, 316 (89%). While all births at the
two facilities were documented in the routine registers,
demographic information was not available for the women
not screened because a survey-trained midwife was not on
duty. Table 1 shows the characteristics of the 435 women
enrolled into the study. The median age was 23 years
with a range from 16–44 years; 42 (10%) women were
<18 years, and 33 (8%) were ≥35 years old. Thirty-seven
per cent of women were pregnant for the first time (primi-
gravid), and 51% were pregnant for the first or second
time (paucigravid). Thirty-four (8%) women did not take
any SP-IPTp during pregnancy; 115 (26%), 142 (33%) and
144 (33%) women took one, two or three + doses of SP-
IPTp, respectively. In all, 435 enrolled women took 840
doses of SP-IPTp. Of these, 46 (5%) doses from 33 women
were validated from self-report as being distinct from
SP-IPTp doses recorded on the ANC card (13 additional
doses were reported but could not be validated). Other
subject characteristics are reported in Table 1.
Infant and maternal outcomes are reported in Table 2.
Of infants born in the cohort, 8% were LBW, 14% were
preterm and 18% were SGA. There were a total of 133
(31%) infants born with a composite poor birth outcome
(any of LBW, preterm or SGA). Of 31 LBW babies born
alive, survivorship at six weeks was known for 28; 24
(86%) were alive at six weeks after birth. There were a
total of 15 infant deaths in the study: nine were still-
births (eight ≥28 weeks of gestation, one was <28 weeks
of gestation), and six infants died immediately after, or
within six weeks, of birth. No maternal deaths oc-
curred among the cohort. At the time of delivery, more
than one-third of all women had moderate anaemia,
157 (36%) women, while 14 (3%) women had severe
anaemia.
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and 19 (4%) had a positive P. falciparum maternal periph-
eral, cord and placental blood smear, respectively; no other
malaria species were detected. Twenty-eight (7%) subjects
had any positive blood smear. More than one-third of all
placental histopathology specimens were abnormal for
malaria infection 162 (37%), the majority of these being
classified as past infection (class 4), 112 (26%). Placental
histopathology identified 18 (4%) active infections (class 1),
and 32 (7%) chronic infections (classes 2 and 3).
An unadjusted analysis examining the effects of SP
exposure dichotomized in various ways and its effects onTable 3 Unadjusted model: SPa-IPTpb doses (categorical varia
Unadjusted model IPTp <2 vs ≥ 2 SP doses
n, PRc (95% CId)
Placental infectione
All gravidity 435, 0.78 (0.61-0.99)
Paucigravid 218, 0.67 (0.51-0.88)
Multigravid 214, 0.93 (0.60-1.44)
Low birth weight (<2,500 g)
All gravidity 435, 0.41 (0.22-0.79)
Paucigravid 218, 0.27 (0.09-0.77)
Multigravid 214, 0.51 (0.21-1.19)
Preterm (<37 weeks)
All gravidity 429, 0.51 (0.32-0.81)
Paucigravid 216, 0.81 (0.43-1.51)
Multigravid 210, 0.26 (0.12-0.56)
Small for gestational age
All gravidity 428, 0.95 (0.62-1.45)
Paucigravid 216, 1.11 (0.62-1.99)
Multigravid 209, 0.79 (0.41-1.52)
Composite birth outcomef
All gravidity 435, 0.74 (0.56-0.98)
Paucigravid 218, 0.99 (0.67-1.45)
Multigravid 214, 0.50 (0.32-0.79)
Anemia (Hb <11 g/dl)
All gravidity 434, 0.89 (0.70-1.13)
Paucigravid 217, 0.75 (0.55-1.03)
Multigravid 214, 1.06 (0.74-1.53)
Any infectiong
All gravidity 435, 0.78 (0.61-0.99)
Paucigravid 218, 0.66 (0.50-0.86)
Multigravid 214, 0.95 (0.62-1.47)
aSP = sulphadoxine pyrimethamine.
bIPTp = intermittent preventive treatment for malaria in pregnancy.
cPR = prevalence ratio.
dDenotes 95% confidence interval.
ePlacental infection outcome: classes 1–4 vs class 5.
fComposite birth outcome defined as infants born with any of: LBW, SGA, or preterm
gAny infection defined as: pathology classes 1–4, blood smear positive (maternal, pthe outcomes of interest is summarized in Table 3. Two
or more SP-IPTp doses among all women was associated
with a protective effect for placental infection, LBW, pre-
term delivery, composite poor birth outcome, and any
infection. Three doses of SP-IPTp compared to < three
doses remained significantly associated with a reduction
of LBW, preterm deliveries and composite poor birth out-
come, for women of all gravidity. The difference between
two and three or more SP-IPTp doses was not signifi-
cantly different for any outcome or gravidity level.
Outcomes also varied by gravidity (Table 3). Paucigravid
women were more likely to be associated with protectionbles) associated with outcomes of interest
IPTp <3 vs ≥3 SP doses
n, PR (95% CI)
IPTp 2 vs ≥3 SP doses
n, PR (95% CI)
435, 0.80 (0.61-1.06) 286, 0.89 (0.64-1.23)
218, 0.80 (0.57-1.12) 147, 0.98 (0.66-1.47)
214, 0.81 (0.50-1.30) 137, 0.79 (0.46-1.36)
435, 0.35 (0.14-0.88) 286, 0.49 (0.17-1.41)
218, 0.36 (0.08-1.56) 147, 0.75 (0.13-4.38)
214, 0.23 (0.05-0.96) 137, 0.25 (0.05-1.16)
429, 0.40 (0.21-0.77) 281, 0.50 (0.24-1.02)
216, 0.64 (0.31-1.34) 146, 0.66 (0.29-1.47)
210, 0.16 (0.04-0.67) 133, 0.29 (0.06-1.39)
428, 0.83 (0.53-1.30) 281, 0.81 (0.48-1.35)
216, 0.94 (0.53-1.69) 146, 0.88 (0.46-1.67)
209, 0.68 (0.32-1.43) 133, 0.70 (0.29-1.66)
435, 0.64 (0.45-0.90) 286, 0.69 (0.47-1.01)
218, 0.82 (0.55-1.25) 147, 0.79 (0.50-1.25)
214, 0.43 (0.23-0.80) 137, 0.55 (0.27-1.12)
434, 0.87 (0.67-1.13) 285, 0.90 (0.67-1.22)
217, 0.72 (0.49-1.06) 146, 0.79 (0.51-1.22)
214, 1.08 (0.75-1.54) 137, 1.06 (0.69-1.62)
435, 0.79 (0.60-1.04) 286, 0.87 (0.64-1.20)
218, 0.80 (0.57-1.10) 147, 0.99 (0.67-1.46)
214, 0.79 (0.49-1.26) 137, 0.75 (0.44-1.28)
.
lacental or cord blood).
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ities, or any infection. In contrast, multigravid women
were more likely to be protected from preterm delivery,
and composite poor birth outcome. In addition, among
multigravid women, protection from LBW was not associ-
ated with two doses of SP-IPTp, but was observed with
three or more SP-IPTp doses.
Outcomes significant in the unadjusted analysis were
assessed with Poisson multivariate regression models, in-
cluding gravidity as an interaction term with SP-IPTp, and
age group (<18, 18–35, >35), sleeping under an ITN the
previous night at home, living in a home that is IRS
treated, living in an urban area, facility of enrolment,
delivering during the wet season (November–April), and
marital status (Table 4). Self-reported SP-IPTp doses were
considered and tested as a cofactor, but were not found to
be significant (at a 0.1 level) for any outcome of interest.
All three SP-IPTp dosing comparisons were assessed, al-
though for some outcomes, SP-IPTp two versus ≥ three
doses could not be computed because of an inadequate
number of responses. In paucigravid women two or
more SP-IPTp doses were protective for LBW and any
infection. Among multigravid women, ≥two and ≥
three SP-IPTp doses were associated with fewer pre-
term deliveries and composite poor birth outcomes.
Three or more doses of SP-IPTp compared to two
doses were not significant for either of the outcomesTable 4 Multivariate regression: SPa-IPTpb doses (categorical
Adjusted modelc <2 vs ≥2 doses PRd (95% CIe)
Placental infectionf
Paucigravid 0.77 (0.58- 1.01)
Multigravid 1.00 (0.66-1.52)












aSP = sulphadoxine pyrimethamine.
bIPTp = intermittent preventive treatment for malaria in pregnancy.
c Model adjusted for: Age group (<18, 18–35, >35), gravidity as an interaction term,
IRS, urban, facility, delivered during the wet season, marital status.
dPR = prevalence ratio.
eCI = 95% confidence interval.
fPlacental infection outcome: histopathology classes 1–4 vs class 5.
gComposite birth outcome defined as infants born with any of: LBW, SGA or preterm
hAny infection defined as: pathology classes 1–4, blood smear positive (maternal, pfor which it could be computed (placental infection,
and any infection).
Table 5 summarizes the results of an unadjusted assess-
ment of the dose–response effect of SP-IPTp on out-
comes, considering SP-doses as a continuous variable, and
the interaction of gravidity and number of SP-IPTp doses
taken into account. Among all women, the trend p-values
was significant (<0.05) for outcomes of placental infection
by histopathology, LBW, preterm delivery, composite poor
birth outcome, and any infection.
Multivariate Poisson regression analysis with the same
covariates as previously mentioned (age group (<18,
18–35, >35), sleeping under an ITN the previous night at
home, living in a home that is IRS treated, living in an
urban area, facility of enrolment, delivering during the wet
season, and marital status) shows that protection from
LBW was significantly associated with increased SP-IPTp
doses for both paucigravid and multigravid women
(Table 6). For each dose of SP-IPTp there was a 46 and
37% decrease in the frequency of LBW among paucigravid
and multigravid women, respectively. Placental infection
by histopathology and any infection were not significantly
associated with SP-IPTp doses in this analysis. Among
multigravid women, the dose–response effect from SP-
IPTp remained significantly associated with protection
from preterm delivery and the composite poor birth
outcome.variables) associated with outcomes of interest
<3 vs ≥ 3 doses PR (95% CI) 2 vs ≥3 doses PR (95% CI)
0.89 (0.64-1.23) 1.06 (0.71-1.57)
0.87 (0.55-1.39) 0.83 (0.49-1.39)
0.43 (0.10-1.81) Could not compute
0.26 (0.06-1.11) Could not compute
0.70 (0.34-1.44) Could not compute
0.15 (0.04-0.55) Could not compute
0.84 (0.54-1.31) Could not compute
0.43 (0.24-0.80) Could not compute
0.88 (0.65-1.21) 1.06 (0.72-1.55)
0.86 (0.54-1.36) 0.79 (0.48-1.33)
sleeping under an ITN the last night at home, living in a home treated with
.
lacental or cord blood).
Table 5 Unadjusted trend analysis: SPa-IPTpb doses
(continuous variable) associated with outcomes of interest





All gravidity 0.87 (0.77-0.99) 0.03
Paucigravid 0.84 (0.72-0.97) 0.02
Multigravid 0.91 (0.73-1.12) 0.37
Low birth weight (<2,500 g)
All gravidity 0.59 (0.43-0.81) <0.01
Paucigravid 0.50 (0.29-0.85) 0.01
Multigravid 0.62 (0.42-0.90) 0.01
Preterm (<37 weeks)
All gravidity 0.65 (0.51-0.81) <0.01
Paucigravid 0.82 (0.60-1.12) 0.21
Multigravid 0.47 (0.33-0.66) <0.01
Small for gestational age
All gravidity 0.93 (0.75-1.15) 0.49
Paucigravid 0.99 (0.74-1.32) 0.94
Multigravid 0.85 (0.62-1.17) 0.32
Composite birth outcomee
All gravidity 0.80 (0.70-0.92) <0.01
Paucigravid 0.92 (0.76-1.11) 0.37
Multigravid 0.67 (0.54-0.84) <0.01
Anemia (Hb <11 g/dl)
All gravidity 0.93 (0.82-1.05) 0.24
Paucigravid 0.84 (0.72-0.99) 0.04
Multigravid 1.03 (0.86-1.23) 0.74
Any infectionf
All gravidity 0.87 (0.77-0.98) 0.03
Paucigravid 0.84 (0.72-0.96) 0.01
Multigravid 0.91 (0.74-1.12) 0.38
aSP = sulphadoxine pyrimethamine.
bIPTp = intermittent preventive treatment for malaria in pregnancy.
cCI = 95% confidence interval.
dPlacental infection outcome: histopathology classes 1–4 vs class 5.
eComposite birth outcome defined as infants born with any of: LBW, SGA,
or preterm.
fAny infection defined as pathology classes 1–4, blood smear positive
(maternal, placental or cord blood).
Table 6 Multivariate logistic regression trend analysis:
SPa-IPTpb doses (continuous variable) associated with
outcomes of interest





Paucigravid 0.88 (0.77-1.04) 0.13
Multigravid 0.94 (0.76-1.16) 0.58
Low birth weight (<2,500 g)
Paucigravid 0.54 (0.33-0.90) 0.02
Multigravid 0.63 (0.41-0.97) 0.04
Preterm (<37 weeks)
Paucigravid 0.85 (0.62-1.17) 0.32
Multigravid 0.48 (0.34-0.69) <0.0001
Composite birth outcomef
Paucigravid 0.94 (0.77-1.15) 0.56
Multigravid 0.66 (0.53-0.82) <0.001
Any infectiong
Paucigravid 0.89 (0.77-1.03) 0.13
Multigravid 0.95 (0.77-1.17) 0.63
aSP = sulphadoxine pyrimethamine.
bIPTp = intermittent preventive treatment for malaria in pregnancy.
cModel adjusts for: Age group (<18, 18–35, >35), gravidity as an interaction
term, sleeping under an ITN the last night at home, living in a home treated
with IRS, urban, facility, delivered during the wet season, marital status.
dCI = 95% confidence interval.
ePlacental infection outcome: histopathology classes 1–4 vs class 5.
fComposite birth outcome defined as infants born with any of: LBW, SGA,
or preterm.
gAny infection defined as pathology classes 1–4, blood smear positive
(maternal, placental or cord blood).
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outcomes was assessed among 392 women who had
taken ≥ one SP-IPTp dose, and for which the complete
date of the SP-IPTp dose was known. A total of 172
(44%) women took their last dose of SP-IPTp within
the four weeks prior to birth. The only outcome that
was significantly associated with the timing of the last
SP-IPTp dose (Pearson’s Chi-square test) was parasite
positivity (parasites found on any blood smear, or histo-
pathology classes 1–3); 16.8% of women were parasite
positive among those who did not take SP-IPTp duringthe four weeks prior to birth versus 8.7% positive
among those who did take SP-IPTp during the four
weeks prior to birth (p = 0.02). There was no effect of
the timing of SP-IPTp on the following outcomes:
placental infection, moderate anaemia, LBW, pre-term
delivery, SGA, composite poor birth outcome, and any
infection.
Discussion
This study found that SP-IPTp in Mansa, Zambia pro-
tected pregnant women from poor birth outcomes, and
that the degree and type of protection afforded by SP-
IPTp was dependent on the specific outcome, gravidity,
and number of SP-IPTp doses taken. Two or more doses
of SP-IPTp were determined to be a threshold associated
with protection of paucigravid women from outcomes of
placental malaria, LBW, and any malaria infection. Like-
wise, at least two or more doses of SP-IPTp were associ-
ated with protection of multigravid women from preterm
delivery and composite poor birth outcome. In addition,
analysis of SP-IPTp as a continuous variable, to assess the
trend-effect for each subsequent dose, showed that each
dose of SP-IPTp confers a protective benefit for LBW
Mace et al. Malaria Journal  (2015) 14:69 Page 9 of 11among women of any gravidity (Table 6). Furthermore,
the setting in which these outcomes were observed was
described in an SP-IPTp therapeutic efficacy study, con-
ducted in parallel to this one, in Mansa, Zambia, showing
that among asymptomatic, parasitaemic, HIV-negative
women enrolled in their second or third trimester, SP-
IPTp had a 26% failure rate in terms of recurrent parasit-
aemia, and found an intermediate prevalence of genetic
mutations that contribute to SP resistance [25].
This work provides valuable information on the contin-
ued effectiveness of SP-IPTp in transmission settings that
have moderate prevalence of dhps and dhfr mutant alleles.
Previous studies have examined SP-IPTp outcomes in
areas of high prevalence of the quintuple SP mutations
[22,38-42], sometimes demonstrating that protective
effectiveness is waning or SP-IPTp is harmful [22,43]. Al-
ternatively, in the West Africa region, while SP mutations
are not uncommon, there is lower prevalence of the
quintuple mutation [40,44] and continued effectiveness of
SP-IPTp is likely to remain high [45,46].
In 2012 WHO clarified SP-IPTp recommendations for
areas of moderate-to high transmission, continuing the
recommendation that women should receive four ante-
natal care visits spaced at least one month apart in the
second and third trimester, but specifying that a dose of
SP-IPTp should be administered at each visit [7]; Zambia
adopted a policy aligned with the current WHO recom-
mendations. Results presented herein support the current
SP-IPTp policies and provide further evidence that preg-
nant women continue to benefit from three or more doses
of SP-IPTp, by showing that SP-IPTp had a protective
dose–response effect among all women for the outcome
of LBW (Table 6). Operationally, the clarified guidelines
should be straightforward for antenatal clinics to imple-
ment, increasing the likelihood that women will benefit
from an increased number of SP-IPTp doses. To im-
prove SP-IPTp uptake, measures such as supervision of
healthcare workers to improve provision of SP-IPTp,
improvement of supply chain management to prevent
SP stock-outs, and text messages serving as antenatal
care reminders, could be considered.
Results herein illustrate differences in consideration of
outcomes and gravidity. For the primary outcome of pla-
cental infection, at least two doses of SP-IPTp are protect-
ive for paucigravid women and not multigravid women. In
addition, paucigravid women were similarly protected from
LBW and any infection, in contrast to multigravid women.
The outcomes where SP-IPTp is significantly protective
only among multigravid women are preterm delivery and
the composite poor birth outcome (which includes, and is
driven by preterm delivery) (Table 4). While there is not a
single compelling reason to explain this gravidity difference
for the preterm outcome, the following explanations are
plausible: (i) among primigravid women, it is possible thatthere was not sufficient power to detect a protective effect
against preterm delivery, (ii) preterm is assessed using last
menstrual period and Ballard scores, methodologies which
can be subject to error, and could have resulted in mis-
classification bias. These results support the conclusion
that SP-IPTp confers a protective effect among women of
any gravidity status, although the protection is stronger
among paucigravid women for the outcomes of LBW,
placental infection, and any infection.
This study has the following limitations: it was designed
to be observational where women were not randomized to
receive different amounts of SP-IPTp doses. While
relatively equal distribution of SP-IPTp for one, two or
three or more doses (115, 142, and 144 women, respect-
ively) was observed, only 34 women received zero doses of
SP-IPTp, limiting the ability to analyse the effectiveness of
any SP-IPTp doses compared to the group of women who
received none. It is possible that there is misclassification
of some SP-IPTp doses, especially for those 46 doses not
recorded on ANC cards. Treating SP-IPTp dosage as a
continuous variable in modelling may mask potential
non-linear effects. It was not possible to determine the
quality of the SP doses provided at antenatal clinics across
the Mansa District area. However, the dose-timing analysis
found that taking SP-IPTp in the four weeks prior to birth
was associated with a decrease in parasite positivity,
suggesting generally that the administered SP had anti-
parasitic properties. One-third of all births registered dur-
ing the study period at the two facilities were not screened
for enrolment, and since demographic information was
not available for the non-screened women it is impossible
to evaluate whether women enrolled were representative
of the true population of women giving birth at the two
sites. Although all enrolled women had an HIV-negative
test result recorded during their pregnancy, it is possible
that HIV-positive women were enrolled; however the
effect of this error would have biased results towards the
null hypothesis. Additionally, it was not possible to control
for antenatal visits, and this could affect the study out-
comes, including birth weight [47].
Conclusions
In Mansa, Zambia, an area of moderate SP resistance, two
or more doses of SP-IPTp are associated with a protective
effect from malaria in pregnancy, especially among pauci-
gravid women. Each dose of SP-IPTp contributed to a 46
and 37% decrease in the frequency of LBW among pauci-
gravid and multigravid women, respectively. The results
herein suggest that SP-IPTp confers protective benefits to
pregnant women and their infants in this transmission
setting, despite a previously described intermediate
prevalence of genetic mutations that contribute to SP
resistance; the SP-IPTp strategy should continue to be
supported. To protect women from deleterious effects of
Mace et al. Malaria Journal  (2015) 14:69 Page 10 of 11malaria during pregnancy, update of SP-IPTp should be
improved; SP supply chain management, implementing
text message antenatal reminders, and supervision of
healthcare providers could be considered to ensure
women have optimal access to SP-IPTp.
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